Table 1.
Clinical and epidemiological characteristics of all HIV/HCV-coinfected patients stratified by FTO genotype
| Characteristics | All patients (number = 261) | TT (number = 101) | AT (number = 123) | AA (number = 37) | P -value |
|---|---|---|---|---|---|
| Gender (male) | 74.7% (195) | 73.3% (74) | 74% (91) | 81.1% (30) | 0.625 |
| Age (years) | 40.9 (6.9) | 40.6 (6.17) | 41.1 (7.69) | 42.1 (6.6) | 0.849 |
| HIV acquired by IVDU | 85.4% (223) | 85.1% (86) | 83.7% (103) | 91.9% (34) | 0.556 |
| Years since HCV infection | 21 (8.4) | 21.3 (8.35) | 20.9 (8.25) | 21.6 (7.8) | 0.670 |
| Prior AIDS | 29.1% (76) | 69.3% (70) | 74.8% (92) | 37.8% (14) | 0.302 |
| cART | 84.7% (221) | 82.2% (83) | 87.8% (108) | 81.1% (30) | 0.410 |
| Time on cART (years) | 4.8 (5) | 4.6 (4.9) | 5 (4.8) | 4.7 (5.1) | 0.350 |
| Current cART protocols | |||||
| Any NRTIs + any PI | 24.5% (64) | 25.7% (26) | 25.2% (31) | 18.9% (7) | 0.691 |
| Any NRTIs + PI + NNRTI | 1.1% (3) | 1% (1) | 1.6% (2) | 0% (0) | 0.705 |
| Any NRTIs + any NNRTI | 51.3% (134) | 50.5% (51) | 51.2% (63) | 54.1% (20) | 0.933 |
| Only NRTIs | 7.3% (19) | 5% (5) | 9.8% (12) | 5.4% (2) | 0.346 |
| Specific antiretroviral drugs | |||||
| Zidovudine | 27.2% (71) | 25.7% (26) | 30.1% (37) | 21.6% (8) | 0.547 |
| Stavudine | 26.1% (68) | 24.8% (25) | 28.5% (35) | 21.6% (8) | 0.659 |
| Didanosine | 16.9% (44) | 18.8% (19) | 13.8% (17) | 21.6% (8) | 0.431 |
| Tenofovir | 26.8% (70) | 28.7% (29) | 22% (27) | 37.8% (14) | 0.138 |
| Abacavir | 16.1% (42) | 9.9% (10) | 21.1% (26) | 16.2% (6) | 0.075 |
| Efavirenz | 30.3% (79) | 29.7% (30) | 30.1% (37) | 32.4% (12) | 0.951 |
| Ritonavir (r) | 6.1% (16) | 5.9% (6) | 7.3% (9) | 2.7% (1) | 0.588 |
| Lopinavir/r | 12.3% (32) | 10.9% (11) | 12.2% (15) | 16.2% (6) | 0.700 |
| Saquinavir | 1.1% (3) | 0% (0) | 1.6% (2) | 2.7% (1) | 0.332 |
| Fosamprenavir | 2.3% (6) | 3% (3) | 2.4% (3) | 0% (0) | 0.582 |
| HIV markers | |||||
| Nadir CD4+ T-cells (cells/μL) | 204 (223) | 210 (262) | 195 (221) | 210 (201) | 0.157 |
| Nadir CD4+ <200 cells/μL | 49% (128) | 46.5% (47) | 52% (64) | 45.9% (17) | 0.658 |
| CD4+ T cells/μL | 465 (325) | 460 (435) | 472 (234) | 456 (251) | 0.313 |
| CD4+ ≥500 cells/μL | 43.5% (113) | 55.4% (56) | 57.4% (70) | 43.2% (16) | 0.959 |
| HIV-RNA <50 copies/mL | 76.9% (200) | 75% (75) | 78% (96) | 78.4% (29) | 0.844 |
| HCV markers | |||||
| HCV-genotype 1/4 | 73.4% (185) | 68.8% (66) | 75% (90) | 80.6% (29) | 0.339 |
| HCV-RNA ≥500,000 UI/ml | 75.1% (187) | 29.6% (29) | 23.5% (27) | 83.3% (30) | 0.275 |
| IFNL3 rs12980275 (AA) | 47.5% (122) | 47.5% (48) | 50% (61) | 38.2% (13) | 0.557 |
Categorical variables are expressed in percentage (absolute count).; continuous variables are expressed in median (interquartile range) P-values were estimated with Chi-square test for categorical variable and linear regression test for continuous variable. AIDS, acquired immunodeficiency syndrome; cART, combination antiretroviral therapy; HCV, hepatitis C virus; HCV-RNA, HCV plasma viral load; HIV, human immunodeficiency virus; HIV-RNA, HIV plasma viral load; IVDU, intravenous drug users; NNRTI, no nucleoside analog reverse-transcriptase inhibitors; NRTI, nucleoside analog reverse-transcriptase inhibitors; PI, protease inhibitors.